{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.3","upperLimit":"98.8","value":"90"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"A patient will be counted only once for a given toxicity for the worst grade of that toxicity reported for that patient.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Selumetinib)"}],"paramType":"NUMBER","populationDescription":"One patient was deemed ineligible by the Study Chair and is excluded from this analysis.","reportingStatus":"POSTED","timeFrame":"From enrollment to the end of treatment, up to 2 years","title":"Percentage of Participants With Treatment-related Adverse Events as Accessed by Common Terminology Criteria for Adverse Events (CTCAE) Version (v) 5.0","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}